GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE193566 Query DataSets for GSE193566
Status Public on Mar 08, 2023
Title Longitudinal gene expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but falling short of providing a consistent relapse-specific genetic signature. In our study, we have focussed attention on the changes in gene expression profile accompanying DLBCL relapse using archival paired diagnostic/relapse specimens from 38 de novo DLBCL patients. Cell of origin remained stable from diagnosis to relapse in 80% of patients, with only a single patient showing COO switching from ABC to GCB. Analysis of the transcriptomic changes that occur following relapse suggest ABC and GCB relapses are mediated via different mechanisms. We developed a 30-gene discriminator for ABC-DLBCLs derived from relapse-associated genes, that defined clinically distinct high and low risk subgroups in ABC-DLBCLs at diagnosis in datasets comprising both population-based and clinical trial cohorts. This signature also identified a population of <60-year-old patients with superior PFS and OS treated with Ibrutinib-R-CHOP as part of the PHOENIX trial. Altogether this new signature adds to the existing toolkit of putative genetic predictors now available in DLBCL that can be readily assessed as part of prospective clinical trials.
Overall design Gene expression profiels for 76 paired diagnosis and relapse DLBCL biopsies from 38 patients were generated using the Ion AmpliSeqâ„¢ Human Gene Expression assay.
Contributor(s) Bewicke-Copley F, Korfi K, Araf S, Hodkinson B, Kumar E, Cummin T, Ashton-Key M, Barrans S, Van Hoppe S, Burton C, Elshiekh M, Rule S, Crosbie N, Clear A, Calaminici M, Runge H, Hills RK, Scott DW, Rimsza LM, Menon G, Sha C, Davies J, Nagano A, Davies A, Painter D, Smith A, Gribben J, Naresh KN, Westhead DR, Okosun J, Steele A, Hodson DJ, Balasubramanian S, Johnson P, Wang J, Fitzgibbon J
Citation(s) 35947123
Submission date Jan 12, 2022
Last update date Jun 07, 2023
Contact name Findlay Bewicke-Copley
Organization name Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London
Street address John Vane Science Centre, Barts Cancer Institute
City London
ZIP/Postal code EC1M 6BQ
Country United Kingdom
Platforms (1)
GPL17303 Ion Torrent Proton (Homo sapiens)
Samples (76)
GSM5814228 Patient1D
GSM5814229 Patient1R
GSM5814230 Patient2D
BioProject PRJNA796606

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE193566_RAW.tar 6.5 Mb (http)(custom) TAR (of TXT)
GSE193566_all_batchCorrectedCounts.txt.gz 5.6 Mb (ftp)(http) TXT
GSE193566_all_rawCounts.txt.gz 1.9 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data provided as supplementary file
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap